Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences cEO total annual compensation ($) ($)
DEF 14A Proxy Statement (CEO Pay Ratio)
Latest, FY2025
28,437,198
Period ended Dec 31, 2025
Change on a year earlier
+20.0%
23,689,392 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CEO total annual compensation ($) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28,437,198 | +20.0% | Proxy Statement (DEF 14A) (gild014721-def14a.htm, filed 2026-03-20) ↗ |
| FY2024 | Dec 31, 2024 | 23,689,392 | +4.8% | Proxy Statement (DEF 14A) (gild013520-def14a.htm, filed 2025-03-27) ↗ |
| FY2023 | Dec 31, 2023 | 22,607,690 | +4.6% | Proxy Statement (DEF 14A) (lgild2024_def14a.htm, filed 2024-03-28) ↗ |
| FY2022 | Dec 31, 2022 | 21,621,253 | +12.4% | Proxy Statement (DEF 14A) (gild4141721-def14a.htm, filed 2023-03-23) ↗ |
| FY2021 | Dec 31, 2021 | 19,229,466 | +1.2% | Proxy Statement (DEF 14A) (gild3988061-def14a.htm, filed 2022-03-24) ↗ |
| FY2020 | Dec 31, 2020 | 18,998,905 | -35.3% | Proxy Statement (DEF 14A) (gild3818501-def14a.htm, filed 2021-03-30) ↗ |
| FY2019 | Dec 31, 2019 | 29,361,393 | – | Proxy Statement (DEF 14A) (gild3646261-def14a.htm, filed 2020-03-24) ↗ |
Cite this data
StockData. (2026). Gilead Sciences CEO total annual compensation ($) ($), annual FY2019–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gov_ceo_comp
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.